No Data
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn Into More Strength?
Aquestive Therapeutics to Present New Findings at AAAAI Meeting
Institutional Investors Own a Significant Stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Promising Pipeline and Solid Financials: Analyst's Buy Rating on Aquestive Therapeutics
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Aquestive Therapeutics: Promising Growth Trajectory With Strategic Initiatives and Strong Market Potential
